{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:36:27Z","timestamp":1776202587476,"version":"3.50.1"},"reference-count":25,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis","award":["Grant #01.2021"],"award-info":[{"award-number":["Grant #01.2021"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,7,6]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>There is a need for a widely accepted comprehensive disease activity measure for use in daily practice in patients with psoriatic arthritis (PsA). For this reason, the 3-item Visual Analogue Scale (3VAS) and 4-item Visual Analogue Scale (4VAS) were developed. This study aimed to test construct validity and responsiveness of the 3VAS and 4VAS in a population of patients with newly diagnosed PsA receiving usual care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Components of the 3VAS (physician global, patient global, patient skin) and 4VAS (physician global, patient pain, patient joint, patient skin) were scored on 0\u201310 VAS scales. Agreement of low disease activity (LDA) state between 3VAS\/4VAS and other composite measures was tested using Venn diagrams. Construct validity and responsiveness (3-month interval) were assessed using Spearman correlation coefficients and standardised response means (SRM) with effect sizes (ES), respectively, following hypothesis generation. Both 3VAS\/4VAS were also compared with several patient-reported outcome measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 629 patients were used. Both 3VAS (ES=0.48, SRM 0.52) and 4VAS (ES=0.48, SRM=0.50) showed responsiveness similar to Disease Activity in PSoriatic Arthritis (DAPSA) and Disease Activity Score-28 (DAS28). Both measures had a strong correlation with DAPSA (r=0.80\u20130.87), Psoriatic Arthritis Disease Activity Score (PASDAS) (r=0.89) and Routine Assessment of Patient Index Data 3 (RAPID3) (r=0.84\u20130.92). 3VAS and 4VAS had the highest agreement with PASDAS in categorising patients to LDA at 12 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is the first study assessing the performance of the 3VAS and 4VAS in an observational cohort of patients with early PsA. Both measures have promising performance characteristics, showing strong correlations and good discrimination with existing composite measures. The 4VAS may be the preferred version with better face validity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002972","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T21:30:16Z","timestamp":1698269416000},"page":"e002972","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-9981","authenticated-orcid":false,"given":"Fazira R.","family":"Kasiem","sequence":"first","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-6926","authenticated-orcid":false,"given":"Marc R.","family":"Kok","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-7932","authenticated-orcid":false,"given":"Jolanda J.","family":"Luime","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilja","family":"Tchetverikov","sequence":"additional","affiliation":[{"name":"Rheumatology, Albert Schweitzer Ziekenhuis, Dordrecht, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindy-Anne","family":"Korswagen","sequence":"additional","affiliation":[{"name":"Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasja H.A.M.","family":"Denissen","sequence":"additional","affiliation":[{"name":"Amphia Hospital Breda, Breda, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne P.M.","family":"Goekoop-Ruiterman","sequence":"additional","affiliation":[{"name":"Rheumatology, HAGA Hospital, The Hague, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maikel","family":"van Oosterhout","sequence":"additional","affiliation":[{"name":"Rheumatology, Groene Hart Hospital, Gouda, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faouzia","family":"Fodili","sequence":"additional","affiliation":[{"name":"Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M.W.","family":"Hazes","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Diseases, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2025090312055528000_9.4.e002972.1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"2025090312055528000_9.4.e002972.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171406"},{"key":"2025090312055528000_9.4.e002972.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200121"},{"key":"2025090312055528000_9.4.e002972.4","doi-asserted-by":"crossref","unstructured":"Tillett W , FitzGerald O , Coates LC , et al . Composite measures for clinical trials in Psoriatic arthritis: testing pain and fatigue modifications in a UK multicenter study. J Rheumatol 2021. doi:10.3899\/jrheum.201674 [Epub ahead of print 1 Mar 2021].","DOI":"10.3899\/jrheum.201674"},{"key":"2025090312055528000_9.4.e002972.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.1978"},{"key":"2025090312055528000_9.4.e002972.6","doi-asserted-by":"crossref","unstructured":"Tillett W , FitzGerald O , Coates LC , et al . Composite measures for routine clinical practice in Psoriatic arthritis: testing of shortened versions in a UK multicenter study. J Rheumatol 2021. doi:10.3899\/jrheum.201675 [Epub ahead of print 1 Mar 2021].","DOI":"10.3899\/jrheum.201675"},{"key":"2025090312055528000_9.4.e002972.7","unstructured":"Beaton D , Maxwell L , Grosskleg S , et al . The OMERACT handbook for establishing and implementing core outcomes in clinical trials across the spectrum of rheumatologic conditions. Ottawa, Canada: OMERACT, 2021. Available: https:\/\/omeract.org\/wp-content\/uploads\/2021\/12\/OMERACT-Handbook-Chapter-5_Final_June-2-2021_a.pdf#"},{"key":"2025090312055528000_9.4.e002972.8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/03009742.2020.1803398","article-title":"Lessons learned from clinical phenotypes in early Psoriatic arthritis: the real-world Dutch South West early Psoriatic arthritis study","volume":"50","author":"Kasiem","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025090312055528000_9.4.e002972.9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","article-title":"Assessing disease activity in Psoriatic arthritis: a literature review","volume":"6","author":"Tucker","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090312055528000_9.4.e002972.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"2025090312055528000_9.4.e002972.11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/rheumatology\/kez215","article-title":"Comparison of disease activity measures in early Psoriatic arthritis in usual care","volume":"58","author":"Wervers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312055528000_9.4.e002972.12","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1798-3"},{"key":"2025090312055528000_9.4.e002972.13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User\u2019s guide to correlation coefficients","volume":"18","author":"Akoglu","year":"2018","journal-title":"Turk J Emerg Med"},{"key":"2025090312055528000_9.4.e002972.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090312055528000_9.4.e002972.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449"},{"key":"2025090312055528000_9.4.e002972.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000391","article-title":"MDHAQ\/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sites","volume":"3","author":"El-Haddad","year":"2017","journal-title":"RMD Open"},{"key":"2025090312055528000_9.4.e002972.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2025090312055528000_9.4.e002972.18","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.4103\/ijmr.IJMR_701_15","article-title":"Comparison of disease activity score in 28 joints with ESR (DAS28), clinical disease activity index (CDAI), health assessment questionnaire disability index (HAQ-DI) & routine assessment of patient index data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation","volume":"146","author":"Kumar","year":"2017","journal-title":"Indian J Med Res"},{"key":"2025090312055528000_9.4.e002972.19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/keab557","article-title":"Measuring disease activity in Psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden","volume":"61","author":"Mulder","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312055528000_9.4.e002972.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991"},{"key":"2025090312055528000_9.4.e002972.21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001050","article-title":"Routine assessment of patient index data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice","volume":"5","author":"Boone","year":"2019","journal-title":"RMD Open"},{"key":"#cr-split#-2025090312055528000_9.4.e002972.22.1","doi-asserted-by":"crossref","unstructured":"Tillett W , Coates L , Vis M , et al . POS0228\u2005MINIMAL important difference (MID), minimal detectable change (MDC), and disease activity thresholds for two novel composite instruments (3VAS, 4VAS) in patients with psoriatic arthritis: pooled analysis of three phase 3 studies. abstract. EULAR 2023 European Congress of Rheumatology, 31 May - 3 June. Milan, Italy","DOI":"10.1136\/annrheumdis-2023-eular.2237"},{"key":"#cr-split#-2025090312055528000_9.4.e002972.22.2","doi-asserted-by":"crossref","unstructured":"June 2023:74 doi:10.1136\/annrheumdis-2023-eular.2237","DOI":"10.1136\/annrheumdis-2023-eular.2237"},{"key":"2025090312055528000_9.4.e002972.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2498"},{"key":"2025090312055528000_9.4.e002972.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200928"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:06:07Z","timestamp":1756926367000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,25]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/rmdopen-2022-002972"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002972","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}